Matthew Winkler is Director at Akoya Biosciences, Inc. (AKYA). They have made 1 open-market trade across 1 company since 2023, most recently 2025-07-08.
CIK 0001652067
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $1.0M since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AKYA | BUY | 2023-06-12 | 2023-06-12 | $5.00 | $1.0M | +15.2% | +22.5% | -26.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.